25 Jan 2024 • In a study with 86,930 participants, metformin use was associated with a decreased odds ratio of developing neovascular age-related macular degeneration (nAMD).

Metformin use exhibited a reduced odds ratio in the full sample, and notably, in diabetic cohorts with cumulative doses below 1,080 g over 24 months. These findings revealed a significant protective effect of metformin, particularly in patients without diabetic retinopathy.

Metformin could potentially emerge as a novel preventive strategy for nAMD.

Source: Retina | Read full story